Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Stem Cell Therapy for the Coronavirus COVID-19 Pandemic
BiotechnologyCompany Update

Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

March 18, 2020 12:00 PM

GOLDEN, CO / ACCESSWIRE / March 18, 2020 / Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic. Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging safety and efficacy...

Read more
Calmare Therapeutics CEO Issues Statement
BiotechnologyCompany Update

Calmare Therapeutics CEO Issues Statement

March 16, 2020 2:58 PM

FAIRFIELD, CT / ACCESSWIRE / March 16, 2020 / Responding to the COVID-19 pandemic ("CoronaVirus"), Conrad Mir, President & CEO of Calmare Therapeutics Incorporated, (OTC PINK:CTTC), the pain mitigation company, issued the following statement: To the shareholders, customers, family and friends of Calmare Therapeutics. We hope this email finds you and your family doing well during this troubling and difficult time. Calmare Therapeutics...

Read more
Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020
BiotechnologyConference CallEarnings

Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020

March 16, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2019 after the...

Read more
Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada
BiotechnologyCompany Update

Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada

March 12, 2020 7:30 AM

TORONTO, ON / ACCESSWIRE / March 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo as well as other indications. Vitiligo is a life-altering autoimmune disease that results in the depigmenting of the skin. People who have vitiligo develop white patches of skin...

Read more
Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update
BiotechnologyEarnings

Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update

March 12, 2020 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 12, 2020 AT 8:00 AM EDT BOSTON, MA / ACCESSWIRE / March 12, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, today reported financial results for its fiscal year ended December 31, 2019 and provided an update...

Read more
Amazon Rainforest Could be Gone
BiotechnologyCompany Update

Amazon Rainforest Could be Gone

March 10, 2020 12:00 PM

BANGOR, WALES, UK / ACCESSWIRE / March 10, 2020 / Bangor University: Amazon rainforest could be gone within a lifetime Large ecosystems, such as the Amazon rainforest, will collapse and disappear alarmingly quickly, once a crucial tipping point is reached, according to calculations based on real-world data. Writing in Nature Comms (10.1038/s41467-020-15029-x), researchers from Bangor University, Southampton University and The School of...

Read more
Trxade Group, Inc's Wholly Owned Subsidiaries to Help Reduce Exposure to Current and Future Virus Outbreaks
BiotechnologyCompany Update

Trxade Group, Inc's Wholly Owned Subsidiaries to Help Reduce Exposure to Current and Future Virus Outbreaks

March 10, 2020 8:30 AM

TAMPA, FL / ACCESSWIRE / March 10, 2020 / Trxade Group, Inc. (NASDAQ:MEDS) an integrated drug procurement, delivery and healthcare platform announces the onset of a new membership service by its subsidiaries Bonum Health and DelivMeds. Effective immediately the companies' monthly subscription rate of $19.95 includes an option of three (3) premium visits per month as well as free prescription delivery service through its subsidiaries. Bonum...

Read more
HemaGenetics Technologies Cancels Effective Date for Arrangement with 1208616 B.C. LTD.
BiotechnologyCompany Update

HemaGenetics Technologies Cancels Effective Date for Arrangement with 1208616 B.C. LTD.

March 9, 2020 6:30 PM

VANCOUVER, BC / ACCESSWIRE / March 9, 2020 / HemaGenetics Technologies Corp. (the "Company"), due to ongoing public market turmoil and business uncertainty, has cancelled the previously scheduled effective date of Tuesday, March 10, 2020, for the share distribution under the plan of arrangement with 1208616 B.C. Ltd. ("616BC"). The Company will provide another shareholder update and setting of a new effective date for the 616BC distribution once...

Read more
HemaGenetics Technologies Announces Effective Date for Arrangement with 1208616 B.C. LTD.
BiotechnologyCompany Update

HemaGenetics Technologies Announces Effective Date for Arrangement with 1208616 B.C. LTD.

March 5, 2020 4:05 PM

VANCOUVER, BC / ACCESSWIRE / March 5, 2020 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that it has set the effective date for Tuesday, March 10, 2020 (the "Effective Date") for the share distribution under the plan of arrangement with 1208616 B.C. Ltd. ("616BC"), which is the distribution date for the shareholders of the Company who would receive 8,502,104 common shares of 616BC. Upon completion of the distribution...

Read more
Principal Investigator Dr. Jorge Hernando Ulloa Presents Updated VenoValve Data at the 32nd Annual Meeting of the American Venous Forum
BiotechnologyConferences

Principal Investigator Dr. Jorge Hernando Ulloa Presents Updated VenoValve Data at the 32nd Annual Meeting of the American Venous Forum

March 5, 2020 8:31 AM

VenoValve Patients Continue to Show Improvement at 6 Months and 1 Year IRVINE, CA / ACCESSWIRE / March 5, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve study in Colombia, presented new VenoValve data at the 32nd Annual Meeting of the American...

Read more
Pieris Pharmaceuticals to Host Full-Year 2019 Investor Call and Corporate Update on March 12, 2020
BiotechnologyConference Call

Pieris Pharmaceuticals to Host Full-Year 2019 Investor Call and Corporate Update on March 12, 2020

March 5, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / March 5, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2019 investor call on Thursday, March 12, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access...

Read more
UPDATE: Pacylex Raises US $3.9 Million To Advance New Cancer Therapy PCLX-001 Towards Clinical Trials
BiotechnologyCompany Update

UPDATE: Pacylex Raises US $3.9 Million To Advance New Cancer Therapy PCLX-001 Towards Clinical Trials

March 4, 2020 8:25 AM

Update is to change a hyperlink within the release. Board changes and development partnership with DavosPharma also announced; DavosPharma will oversee the preparation of clinical supplies and regulatory clearances to advance PCLX-001 through development for Phase I clinical trials. EDMONTON, ALBERTA / ACCESSWIRE / March 4, 2020 / PACYLEX PHARMACEUTICALS INC. (Pacylex), a pre-clinical pharmaceutical company, announces it raised over...

Read more
Genprex to Present at the 2020 LD Micro Virtual Conference
BiotechnologyConferences

Genprex to Present at the 2020 LD Micro Virtual Conference

March 4, 2020 8:00 AM

AUSTIN, TX & CAMBRIDGE, MA / ACCESSWIRE / March 4, 2020 / Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced it will be presenting at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex's Chairman and Chief Executive Officer, Rodney Varner, will lead the...

Read more
Materna Medical Launches New Clinical Study for First-Time Moms
BiotechnologyCompany UpdateProduct Announcements

Materna Medical Launches New Clinical Study for First-Time Moms

March 3, 2020 11:00 AM

$2.2M grant from NIH enables pivotal study MOUNTAIN VIEW, CA / ACCESSWIRE / March 3, 2020 / Materna Medical (Materna), a MedTech company developing products to help protect women's pelvic health, announced today they have formally initiated a pivotal study for their Materna Prep device. The National Institutes of Health (NIH) funded pivotal study will enroll around 200 patients over 24-months and is intended to support a De Novo application...

Read more
Midatech Pharma PLC Announces Result of General Meeting
BiotechnologyRegulatory

Midatech Pharma PLC Announces Result of General Meeting

March 2, 2020 11:25 AM

ADR Ratio Change Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 2, 2020 / Midatech Pharma PLC (AIM:MTPH.L; NASDAQ:MTP) ("Midatech" or the "Company"), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that all resolutions were passed at a general meeting of shareholders of the Company held earlier today. Consequently, with effect from tomorrow, 3 March...

Read more
Stem Cell Therapy for Coronavirus Infection
BiotechnologyCompany Update

Stem Cell Therapy for Coronavirus Infection

February 27, 2020 5:40 PM

GOLDEN, CO / ACCESSWIRE / February 27, 2020 /Vitro Diagnostics, Inc. (OTCPK:VODG), dba Vitro Biopharma reports on a potential therapy of Coronavirus (COVID-19) infections by stem cell transplant. While this therapy is not a method to eradicate or cure Coronavirus, there is evidence to support the concept that infected patients may be more likely to combat and survive infection. First, stem cells resist viral attack by the expression of certain...

Read more
HemaGenetics Technologies Announces Share Distribution Record Date with 1208616 B.C. LTD.
BiotechnologyCompany Update

HemaGenetics Technologies Announces Share Distribution Record Date with 1208616 B.C. LTD.

February 27, 2020 3:12 PM

VANCOUVER, BC / ACCESSWIRE / February 27, 2020 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that it has set the share distribution record date for the Arrangement with 1208616 B.C. Ltd. as February 28, 2020, which is the record date for the shareholders of the Company who would receive 8,502,104 common shares of 1208616 B.C. Ltd. ("616BC") upon the effective (distribution and spin out) date of the Arrangement with...

Read more
New Study Shows Predictive Immune Modeling from Cofactor Genomics is Superior to PD-L1 Assays in Predicting Patient Response to Anti-PD-1 Therapy
BiotechnologyCompany Update

New Study Shows Predictive Immune Modeling from Cofactor Genomics is Superior to PD-L1 Assays in Predicting Patient Response to Anti-PD-1 Therapy

February 27, 2020 10:00 AM

Multidimensional Biomarkers Outperform Single Analyte Immunohistochemistry in Head and Neck Cancer SCOTTSDALE, AZ / ACCESSWIRE / February 27, 2020 / Cofactor Genomics, the company bridging the precision medicine gap with Predictive Immune Modeling, today announced preliminary results from a collaborative study with Washington University School of Medicine in St. Louis, which demonstrated the superior performance of the company's...

Read more
Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available
BiotechnologyCompany Update

Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available

February 27, 2020 8:00 AM

FRAMINGHAM, MA / ACCESSWIRE / February 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that the webcast replay from the presentation given by Jeffrey Eisenberg, Chief Executive Officer of Xenetic, at NobleCon16 - Noble Capital Markets' 16th...

Read more
Mota Ventures Signs Letter of Intent for Merger with Stillcanna
BiotechnologyMergers and Acquisitions

Mota Ventures Signs Letter of Intent for Merger with Stillcanna

February 26, 2020 6:00 PM

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF)(FRANKFURT:1WZGR) ("Mota") and Stillcanna Inc. (STIL)(SCNNF)(A2PEWA) ("Stillcanna") are pleased to announce that they have entered into a letter of intent (the "Letter of Intent"), dated effective February 25, 2020, pursuant to which Mota proposes to acquire all of the outstanding share capital of Stillcanna (the "Proposed Transaction"). Strategic...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?